The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma

Citations Over TimeTop 10% of 2018 papers

Abstract

The outcome of patients who progress on front-line immune-based combination regimens (IC) including immune checkpoint inhibitors (CPI) and receive subsequent systemic therapy is unknown. Retrospective analysis of consecutive patients with clear-cell mRCC who progressed on one of seven clinical trials investigating an IC and received ≥1 line of subsequent VEGFR TKI therapy. Thirty-three patients [median age 57 (37–77), 85% male, 73% ECOG 0] were included. For evaluable patients (N = 28), the best response to first subsequent therapy was 29% partial response, 54% stable disease, and 18% progressive disease. The median PFS (mPFS) for first subsequent therapy was 6.4 months (95% CI, 4.4–8.4); no difference in mPFS by prior type of IC (VEGFR TKI-CPI vs. CPI-CPI) was noted (p = 0.310). Significant AEs were observed in 30% of patients, more frequently transaminitis (9%). VEGFR TKIs have clinical activity in mRCC refractory to IC therapy, possibly impacted by the mechanism of prior combination therapy.

Related Papers

• → Current status of systemic therapy in hepatocellular cancer(2020)8 cited
• → Should We Target OligometastaticEGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?(2022)3 cited
• → Melanoma brain metastases: the outcome of whole brain radiation therapy in the era of effective systemic therapy(2021)2 cited
• → Challenges for the radiation oncologist: the role of radiation therapy after primary systemic therapy(2018)
• Comparative evaluation of the efficacy of an incomplete cytoreduction application in combination with systemic therapy and systemic therapy as mono-therapy in patients with metastatic clear-cell renal cell carcinomas(2015)